期刊文献+

瑞波西汀——新型选择性去甲肾上腺素再摄取抑制剂 被引量:14

暂未订购
导出
摘要 目前治疗抑郁症应用最为广泛的二类药物为三环类(TCAs)和SSRIs.尽管某些TCAs如地昔帕明对去甲肾上腺素(NA)有相对的选择,多数TCAs同时抑制多种受体系统,从而导致明显的副作用.SSRIs在治疗抑郁症与TCAs同样有效,而副作用更少,然而,有证据表明SSRIs在某些抑郁亚群比TCAs疗效差些.因此,抑制NA再摄取对某些病人可能有重要的药理效应,而可避免TCAs的种种副作用.
作者 刘燕 高哲石
出处 《上海精神医学》 北大核心 2001年第2期103-105,共3页 Shanghai Archives of Psychiatry
  • 相关文献

参考文献23

  • 1Delgado PL, Michaels T. Reboxetine: a review of efficacy and tolerability. Drugs of Today, 1999, 35(9): 725
  • 2Dostert P, Benedelti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol, 1997, 7(suppl 1): 23
  • 3Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxeetine in healthy volunteer: Single oral doses, linearity and plasma protein. Biopharm Drug Dispos, 1995, 16(6): 443
  • 4Strolin Benedetti M, Frigerio E, Tocchetti P, et al. Steroselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality, 1995, 7(4): 285
  • 5Poggesi I, Pellizzoni C, Fleishaker JC. Pharmacalkinetics of reboxetine in elderely patients with depressive disorders. Int J Clin Pharmacal Ther, 2000, 38(5): 254
  • 6Coulomb F, Ducret F, Laneury JP, et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol, 2000, 40(5): 482
  • 7Wienkers LC, Allievi C, Hauer MJ, et al. Cytochlome P450-medieated metabolism of the individual enantiomers of the antidepressant agent reboxetine by human liver microsomes. Drug Metabo Dispos, 1999, 27(11): 1334
  • 8Von Moltke LL, Greenblatt DJ, Schimder J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet,1995, 29(suppl 1): 33
  • 9Cocciana G, Battalia R, Pevarello P, et al. Comparison of the disposition and of the metabolic patten of Reboxetine, a new antidepressant, in dog, monkey and man. Eur J Drug Metab Pharmacokinet, 1991, 16(3): 231
  • 10Rogoz Z, Wrobel A, Krasicka-Domka M, et al. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely. Pol J Pharmacol, 1999, 51(5): 399

同被引文献146

引证文献14

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部